Can Vitamin-Like supplements save sight in glaucoma?
NCT ID NCT05695027
First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This study tests whether taking nicotinamide and pyruvate supplements can help protect the eyes of people with open-angle glaucoma. About 250 adults aged 35 to 85 will take either the supplements or a placebo for 20 months, while continuing their standard glaucoma medications. The goal is to see if the supplements slow damage to the optic nerve and preserve vision.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nicotinamide and pyruvate (dietary supplements)
- What this could lead to
- If it works, this could offer a simple, safe supplement to help preserve vision in people with glaucoma.
- What could go wrong
- This is a mid-stage trial with 250 participants, so results may not apply to everyone. Supplements may not slow vision loss beyond standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
35 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Willing and able to provide informed consent for participation in the study. 2. Between 35 and 85 years of age. 3. Only one eligible eye per patient will be enrolled. If both eyes qualify, study eye will be elected based on the following characteristics (in order of most to least important): 1) disc hemorrhage, 2) higher intraocular pressure (IOP), 3) without previous filtering surgery, 4) better visual acuity. If both eyes meet these four criteria equally, then the study eye will be determined by random assignment. 4. Have a confirmed diagnosis of primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma. 5. If there is a prior reliable 24-2, the MD should be better than -20dB. 6. Able to perform reliable visual field testing with 24-2 Swedish Interactive Threshold Algorithm (SITA)-Standard SAP (defined as false positive rates \<15%, false negative rates \<30%) at the most recent office visit. 7. Have best corrected visual acuity better than or equal to 20/40 in the study eye. 8. Have an IOP (treated or untreated) ≥ 14 mmHg and within 24 months of the baseline visit and one instance of historical IOP ≥ 16 mmHg by patient report or chart. Exclusion Criteria 1. Glaucoma or cataract surgery anticipated in the next 18 months. 2. Have a diagnosis of significant cataract or media opacity affecting the visual field test or imaging studies. 3. Have a diagnosis of dementia, Alzheimer's, or other neurological disease. 4. Have an inability to take or intolerance to nicotinamide and/or pyruvate. 5. Have undergone incisional glaucoma surgery (trabeculectomy, glaucoma drainage implant, or Xen Gel Stent) within the last 12 months. Phacoemulsification ± canalicular micro-invasive glaucoma surgery (MIGS) is acceptable if performed ≥ 4 months prior to study entry. 6. Prior complicated cataract surgery (e.g., vitrectomy, etc) 7. Have a functioning trabeculectomy, glaucoma drainage implant, or Xen Gel Stent (defined as being on 0-1 glaucoma medications). If these surgeries have failed and the patient is on ≥ 2 classes of glaucoma medication and meets all other entry criteria, he/she is eligible). 8. Retinal pathology that significantly affects visual acuity (worse than 20/40) or visual field. 9. Refractive disorders and disorders other than glaucoma known to affect the visual field (VF) and macular optical coherence tomography (OCT) imaging (e.g., epiretinal membrane, cystoid macular edema, pathologic myopia, cylinder \> 3 diopters, prior history of pars plana vitrectomy with internal limiting membrane peel). 10. IOP at screening or baseline visit ≥ 25 mmHg. 11. Have a known history of liver disease. 12. Are pregnant or are planning to become pregnant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary open-angle glaucoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Irving Medical Center - 622 W 168th St
New York, New York, 10032, United States
-
ColumbiaDoctors Ophthalmology - 880 Third Avenue
New York, New York, 10022, United States
-
Stanford University Department of Ophthalmology
Palo Alto, California, 94303, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One operation for cataract and glaucoma? eye surgeons test a Two-in-One approach
- Home Eye-Pressure checks could slow glaucoma vision loss
- Can a simple eye drop protect the optic nerve in glaucoma?
- Can a One-Time gene edit stop glaucoma in its tracks?
- Zapping the brain to steady the steps of glaucoma patients?
- Can a tiny eye implant replace glaucoma drops?